



Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-35 (canceled)

Claim 36 (currently amended): A method for the identification of ~~an~~ a candidate pharmacological agent to be used in the treatment of AD and/or symptoms thereof, wherein said agent is capable of inhibiting redox-reactive metal-mediated crosslinking A β , said method comprising: (a) adding a redox-reactive metal to a first A β sample; (b) allowing said first sample to incubate for an amount of time sufficient to allow A β crosslinking; (c) adding said redox-reactive metal to a second A β sample, said second sample additionally comprising a candidate pharmacological agent; (d) allowing said second sample to incubate for the same amount of time as said first sample; (e) removing an aliquot from each of said first and second samples; and (f) determining presence or absence of crosslinking in said first and second samples, whereby an absence of A β crosslinking in said second sample as compared to said first sample indicates that said candidate pharmacological agent has inhibited A β crosslinking.

Claim 37 (original): The method of claim 36, wherein at (f), a western blot analysis is performed to determine the presence or absence of crosslinking in the first and second samples.

Claim 38 (canceled)